Introduction The treatment of acromegaly resistant to first and second line therapies may be extremely challenging. Aim, patients and methods To describe our patients successfully treated with a combination therapy of Pasireotide LAR and Pegvisomant and to compare with a control group of patients resistant to conventional somatostatin analogues (SSAs) and controlled with other treatments, such as Pasireotide LAR (in monotherapy) and Pegvisomant (in monotherapy or in association with conventional SSAs). Results A total of 6 patients reached acromegaly disease control with Pasireotide Lar and Pegvisomant combination treatment, after failure with all other treatments. As compared to the 49 patients of the control group, these 6 patients carried giant and invasive pituitary adenomas (both at the cavernous sinus and at other structures). Although not statistically significant, higher values of growth hormone at acromegaly diagnosis, a more elevated Ki67, a higher expression of the subtype 5 and a lower expression of the subtype 2 of the somatostatin receptor were detected in patients on a combination treatment with Pasireotide Lar and Pegvisomant, as compared to the control group. Conclusion Our data reinforced the importance of a personalized treatment of acromegaly, according to clinical, biochemical, molecular and morphological disease markers and suggests that the associative treatment with Pasireotide LAR and Pegvisomant can induce disease control in tumors with a low expression of SSTR2, resistant to conventional SSAs (alone or in association with Pegvisomant) and to new generation SSAs alone (Pasireotide LAR).
22 August 2023 in The Journal of Clinical Endocrinology & Metabolism
Context Skeletal fragility is observed in 30% to 60% of acromegaly patients, representing an emerging complication of the disease that increases disability. Despite several studies having investigated the clinical and hormonal prognostic factors for the occurrence of vertebral fractures (VFs) in acromegaly, very few data are available on their prevention/treatment including the effect of vitamin D (VD) supplementation, which has been reported to have a fracture-protective effect in several studies in patients with osteoporosis. Objective We aimed to investigate the role of cholecalciferol (D3) supplementation in the prevention of incident VFs (i-VFs) in acromegaly. Methods A longitudinal, retrospective and multicenter study was performed on 61 acromegaly patients treated and untreated with D3 supplementation. Results Twenty-six patients were treated with D3 supplementation according to clinical guidelines. The median D3 weekly dosage was 8500 IU (interquartile range [IQR]: 3900). The median duration of D3 supplementation was 94 months (IQR: 38). At last follow-up, i-VFs were diagnosed in 14 patients (23%). I-VFs were less prevalent in patients on D3 supplementation (14.3% of cases) compared to patients not treated with D3 (85.7%; P = .02). The final level of serum V25OH-D was significantly lower in patients who developed i-VFs (28.6 ng/mL, IQR: 4.1) compared to patients who did not develop i-VFs (34.2 ng/mL, IQR: 9.6; P = .05). The logistic regression confirmed the protective role of D3 supplementation on the occurrence of i-VFs (odds ratio: 0.16; 95% CI, 0.03-0.79; P = .01). Conclusion It is likely that D3 supplementation could lead to a reduction in i-VFs in acromegaly.
20 January 2023 in Reviews in Endocrine and Metabolic Disorders
Pituitary tumors are rare neoplasms, with a heterogeneous biological and clinical behavior, due to their clinical course, local invasive growth, resistance to conventional therapies and the risk of disease progression. Recent studies on tumor microenvironment (TME) provided new knowledge on the biology of these neoplasia, that may explain the different phenotypes of these tumors and suggest new biomarkers able to predict the prognosis and the treatment outcome. The identification of molecular markers that act as targets for biological therapies may open new perspectives in the medical treatments of aggressive pituitary tumors.In this paper, we will review data of TME and target therapies in somatotropinomas.
1 August 2014 in The Journal of Clinical Endocrinology & Metabolism
The seminal plasma is made of secretions from the testis, the epididymis, and the male accessory glands, which are dependent on the presence of androgenic stimuli. The objective of this study was to identify new seminal biomarkers for secundary male hypogonadism using proteomic profiling. Seminal plasma samples from patients affected by secundary hypogonadism and normogonadal controls were analyzed by an LTQ Orbitrap XL hybrid mass spectrometer and data were evaluated using bioinformatic tools. The study was performed at a clinical research center. Twenty male patients, aged 25-55 years, affected by secundary hypogonadic were studied. Ten patients were reevaluated after 6 months of T replacement therapy (TRT). Ten normogonadic men were enrolled as a control group. There were no interventions. The list of absent proteins in the samples of hypogonadic patients and identified after TRT was studied. Bioinformatic tools were used to functionally annotate the panel of androgen-dependent proteins. The interaction network of the differentially expressed proteins was built in silico, including the androgen receptor. A lower number of proteins was identified in hypogonadic patients compared with normogonadal men. Among the 61 proteins identified in normogonadal men, 33 proteins were absent in hypogonadic patients. Fourteen of 33 absent proteins were identified in seminal samples after 6 months of TRT. Functional annotation analysis revealed that binding and enzymatic activities are mainly deficient in male hypogonadism. Seven of 14 differentially expressed proteins can fall into one large protein-protein interaction network, which directly involves the androgen receptor. A high resolution mass spectrometry-based proteomic approach was first used to describe the alterations of seminal seminal proteome in secundary male hypogonadism. These proteins represent putative physiological in vivo targets for androgen deficiency.